

## Årsredovisningen för räkenskapsåret 2022-01-01 -2022-12-31

Styrelsen för Xspray Pharma Futurum AB avger härmed följande årsredovisning.

Innehåll:	Sida
Förvaltningsberättelse	2
Balansräkning	3
Noter med redovisningsprinciper	4
Underskrifter	4

Styrelsens säte: Solna

Företagets redovisningsvaluta: Svenska kronor (SEK).

Alla belopp redovisas, om inget annat anges, i kronor (kr).


### Fastställelseintyg för årsredovisning 2022

Årsredovisning för Xspray Pharma Futurum AB , 559178-7642

Undertecknad ledamot i Xspray Pharma Futurum AB intygar att resultaträkningen och balansräkningen i årsredovisningen för 2022 har fastställts på årsstämman den 29 maj 2023. Stämman beslutade att godkänna styrelsens förslag till hur vinsten/förlusten ska fördelas. Jag intygar också att innehållet i årsredovisningen stämmer överens med originalen.

Solna, 14 juni 2023

Ort, datum



Namnsteckning

Per Andersson, Ledamot

2023061614041

## Årsredovisningen för räkenskapsåret 2022-01-01 -2022-12-31

Styrelsen för Xspray Pharma Futurum AB avger härmed följande årsredovisning.

Innehåll:	Sida
Förvaltningsberättelse	2
Balansräkning	3
Noter med redovisningsprinciper	4
Underskrifter	4

*Styrelsens säte: Solna*

*Företagets redovisningsvaluta: Svenska kronor (SEK).*

*Alla belopp redovisas, om inget annat anges, i kronor (kr).*

2023061614042

**Förvaltningsberättelse****Verksamheten***Allmänt om verksamheten*

Xspray Pharma Futurum AB, org nr 559178-7642, med säte i Solna är ett helägt dotterbolag till Xspray Pharma AB (Publ).

Bolaget ska bedriva forsknings-, utvecklings-, försäljnings- och licensieringsverksamhet inom kemi-, läkemedels- och livsmedelsområdet samt därmed förenlig verksamhet. Sedan starten har bolaget varit vilande.

Resultaträkningen utgår i rapporten då inga uppgifter finns att redovisa.

Bolaget registrerades den 7 november 2018, varpå detta år är bolagets fjärde räkenskapsår.

*Väsentliga händelser under räkenskapsåret*

Inga väsentliga händelser under räkenskapsåret har inträffat.

**Förändringar i eget kapital**

		<i>Aktiekapital</i>	<i>Balanserat resultat inkl. årets resultat</i>	<i>Summa eget kapital</i>
Vid årets början	2022-01-01	50 000	-	50 000
Årets resultat		-	-	-
Vid årets slut	2022-12-31	50 000	-	50 000

**Resultatdisposition**

Styrelsen föreslår att fritt eget kapital, kronor - disponeras enligt följande:

Balanseras i ny räkning

Summa       -  
      -

Vad beträffar resultat och ställning i övrigt, hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

**Balansräkning**

Not

2022-12-31 2021-12-31

**TILLGÅNGAR****Kassa och bank**

Kassa och bank

50 000 50 000

**Summa omsättningstillgångar****50 000 50 000****SUMMA TILLGÅNGAR****50 000 50 000****EGET KAPITAL OCH SKULDER****Eget kapital***Bundet eget kapital*

Aktiekapital

50 000 50 000

**Summa bundet eget kapital****50 000 50 000***Fritt eget kapital*

Balanserat resultat

- -

Årets resultat

- -

**Summa fritt eget kapital****- -****Summa eget kapital****50 000 50 000****SUMMA EGET KAPITAL OCH SKULDER****50 000 50 000**

2023061614043

## Noter

### Not 1 Redovisningsprinciper

Årsredovisningen har upprättats i enlighet med Årsredovisningslagen och Bokföringsnämnden allmänna råd BFNAR 2016:10 Årsredovisning i mindre företag.

### Not 2 Personal

Bolaget har inga anställda.

### Not 3 Väsentliga händelser efter räkenskapsårets slut

Inga väsentliga händelser efter räkenskapsårets slut.

### Not 4 Koncernuppgifter

Xspray Pharma Futurum AB är ett helägt dotterbolag till Xspray Pharma AB (publ) org.nr 556649-3671 med säte i Solna och som upprättar koncernredovisning för koncernen där bolaget ingår.

Solna 2023-05-29

DocuSigned by:



Per Andersson  
Styrelseledamot

2023061614044

Certificate Of Completion

Envelope Id: 5B03EDBF59104FDD9CAE3C3B81DA48A6
Subject: Complete with DocuSign: AR Xspray Pharma Futurum. 20221231.pdf
Source Envelope:
Document Pages: 4
Certificate Pages: 4
AutoNav: Enabled
Envelopeld Stamping: Enabled
Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Status: Completed

Envelope Originator:
Niklas Baeckström
Fack 6994
Box 3037
Stockholm, . S-831 03
niklas.baeckstrom@xspray.com
IP Address: 158.174.196.138

Record Tracking

Status: Original
5/29/2023 2:13:47 AM


Holder: Niklas Baeckström
niklas.baeckstrom@xspray.com

Location: DocuSign

Signer Events

Per Andersson
per.andersson@xspray.com
CEO
Security Level: Email, Account Authentication (None)

Signature



Signature Adoption: Drawn on Device
Using IP Address: 158.174.196.138

Timestamp

Sent: 5/29/2023 2:18:09 AM
Viewed: 5/29/2023 2:26:19 AM
Signed: 5/29/2023 2:26:28 AM

Electronic Record and Signature Disclosure:
Accepted: 5/29/2023 2:26:19 AM
ID: 0875ea5c-b91c-4071-9b8b-556468c5bddf

Table with 3 columns: Event Type, Status, and Timestamp. Rows include In Person Signer Events, Editor Delivery Events, Agent Delivery Events, Intermediary Delivery Events, Certified Delivery Events, Carbon Copy Events, Witness Events, Notary Events, Envelope Summary Events, and Payment Events.

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, XSPRAY PHARMA AB (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

**How to contact XSPRAY PHARMA AB:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [karin.krylborn@xspray.com](mailto:karin.krylborn@xspray.com)

**To advise XSPRAY PHARMA AB of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [karin.krylborn@xspray.com](mailto:karin.krylborn@xspray.com) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

**To request paper copies from XSPRAY PHARMA AB**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [karin.krylborn@xspray.com](mailto:karin.krylborn@xspray.com) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

**To withdraw your consent with XSPRAY PHARMA AB**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [karin.krylborn@xspray.com](mailto:karin.krylborn@xspray.com) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify XSPRAY PHARMA AB as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by XSPRAY PHARMA AB during the course of your relationship with XSPRAY PHARMA AB.